Structure of Beta-lactam resistance regulators
β-内酰胺耐药调节剂的结构
基本信息
- 批准号:7229829
- 负责人:
- 金额:$ 21.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-03-01 至 2009-02-28
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAntibiotic ResistanceAntibioticsBacillus licheniformisBacteriologyBindingBiologicalBiologyCellsChimera organismComplexCrystallizationCytoplasmic StructuresCytoplasmic TailDNAData AnalysesDetergentsEndopeptidasesEscherichia coliExhibitsGenetic TranscriptionGenus staphylococcusGoalsHydrolysisIntegral Membrane ProteinKnowledgeLactamaseLactamsLinkMediatingMembraneMembrane ProteinsMicellesMolecularMolecular ConformationMonobactamsPenicillin-Binding ProteinsPenicillinsPeptide HydrolasesPhaseProductionProtease DomainProteinsPublishingRegulationResearch PersonnelResistanceResistance developmentSignal TransductionSignaling MoleculeSolutionsSpecificityStaphylococcal InfectionsStaphylococcus aureusStructureSystemTechniquesTransducersTransmembrane DomainVesicleWaterX-Ray Crystallographybeta-Lactam Resistancebeta-Lactamasebeta-Lactamsin vivoinsightinterestnovel therapeuticspathogenic bacteriaprogramsprotein structureresearch studysensor
项目摘要
DESCRIPTION (provided by applicant): Staphylococcus aureus is among the most prevalent and antibiotic-resistant of pathogenic bacteria. However, beta-lactam antibiotics, the most effective therapy for treating staphylococcal infections, are becoming less effective as resistance to them among staphylococci increases. Resistance is mediated by a beta-lactamase (encoded by blaZ) that hydrolyzes penicillins and an alternate target, penicillin binding protein (PBP2a, encoded by mecA), to which beta-lactam antibiotics bind poorly. Transcription of mecA and blaZ is activated by signal transduction through either MecRl or BlaRl when the bacterial cell is exposed to an inducing beta-lactam. The mec (MecRI and Mecl) and bla (BlaRl and Blal) regulators seem to have a signal transduction mechanism of action that is unique in prokaryotic biology but its mechanism is unclear, due in part to lack of structural information. Answers to this question not only solve an interesting biological question but may also uncover an induction cascade involving other molecules that could link regulation of P-lactam resistance to essential cellular systems. The major goal of this application is to determine the crystal structures of the multidomain integral membrane MecRl and/or BlaRl proteins that will provide a unique insight into the relationship between the parts of the molecules that are responsible for signal reception and signal transduction. An important long-term objective of this application is to provide a structural framework for understanding the molecular mechanisms involved in antibiotic resistance and the development of novel therapeutics. Moreover, the studies will also provide a wealth of other information, including membrane protein production, solubilization and crystallization techniques that are crucial to the continued understanding of integral membrane proteins. The specific aims are: (1) Structure determination of the intact multidomain BlaRl/MecRl proteins, (2) structure determination of rationally chosen fragments of the BlaRl/MecRl protein, and (3) structure determination of complex between BlaRl/MecRl and their homologous repressers Blal/MecI. The clones and subclones of BlaRl and MecRl will be expressed in E. coli and purified. Crystallization experiments to obtain diffraction-quality crystals using the detergent-micelle, cubic-phase, vesicle-fusion, and bicelle techniques will be undertaken. Subsequently, the structures of the proteins will be determined using X-ray crystallography.
描述(由申请人提供):金黄色葡萄球菌是最普遍,抗生素的致病细菌之一。但是,β-内酰胺抗生素是治疗葡萄球菌感染的最有效疗法,随着葡萄球菌抗性的增加,β-内酰胺抗生素变得越来越有效。电阻是由β-内酰胺酶(由Blaz编码)介导的,该β-内酰胺酶水解青霉素和替代靶标,青霉素结合蛋白(PBP2A,由MECA编码),β-内酰胺抗生素结合不佳。当细菌细胞暴露于诱导的β-内酰胺中时,MECA和BLAZ的转录通过通过MECRL或BLARL的信号转导激活。 MEC(MeCRI和MECL)和BLA(BLARL和BLAL)调节剂似乎具有信号转导的作用机理,该机制在原核生物学中是独一无二的,但其机制尚不清楚,部分原因是缺乏结构信息。这个问题的答案不仅解决了一个有趣的生物学问题,而且还可能揭示涉及其他分子的感应级联,这些分子可以将P-LACTAM耐药性调节与必需细胞系统联系起来。该应用的主要目的是确定多域积分膜MECRL和/或Blarl蛋白的晶体结构,这些膜将对负责信号接收和信号传输的分子部分之间的关系提供独特的见解。该应用的一个重要长期目标是提供一个结构框架,以了解抗生素耐药性和新型治疗剂的发展的分子机制。此外,这些研究还将提供大量其他信息,包括膜蛋白的产生,溶解化和结晶技术,这些技术对于持续了解整体膜蛋白至关重要。具体目的是:(1)完整多域Blarl/MeCRL蛋白的结构确定,(2)(2)结构确定blarl/mecrl蛋白的合理选择的片段,(3)Blarl/mecrl及其同源抑制剂Blal/meci之间的复杂结构确定。 Blarl和Mecrl的克隆和亚克隆将以大肠杆菌表示并纯化。将进行结晶实验,以获得使用洗涤剂 - 薄膜,立方相,囊泡融合和比切尔技术获得衍射质量的晶体。随后,将使用X射线晶体学确定蛋白质的结构。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Martin K Safo其他文献
A Novel Direct Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease - <em>In Vivo</em> Efficacy of Ilx-002 in Humanized Mice
- DOI:
10.1182/blood-2024-202714 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
Osheiza Abdulmalik;Kandace Gollomp;Veronica Bochenek;Conroy O Field;Mariana Macias;Benita Balogun;Salma Roland;Martin K Safo;Yan Zhang;Akua Donkor;Abdelsattar Omar;Moustafa El-Araby;David R. Light;Clark Brown;Andrew N Fleischman - 通讯作者:
Andrew N Fleischman
Martin K Safo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Martin K Safo', 18)}}的其他基金
Hemoglobin Modifiers for Sickle Cell Disease Therapy
用于镰状细胞病治疗的血红蛋白调节剂
- 批准号:
8776137 - 财政年份:2014
- 资助金额:
$ 21.7万 - 项目类别:
Hemoglobin Modifiers for Sickle Cell Disease Therapy
用于镰状细胞病治疗的血红蛋白调节剂
- 批准号:
9250636 - 财政年份:2014
- 资助金额:
$ 21.7万 - 项目类别:
Hemoglobin Modifiers for Sickle Cell Disease Therapy
用于镰状细胞病治疗的血红蛋白调节剂
- 批准号:
9053281 - 财政年份:2014
- 资助金额:
$ 21.7万 - 项目类别:
Hemoglobin Modifiers for Sickle Cell Disease Therapy
用于镰状细胞病治疗的血红蛋白调节剂
- 批准号:
9445715 - 财政年份:2014
- 资助金额:
$ 21.7万 - 项目类别:
Hemoglobin Modifiers for Sickle Cell Disease Therapy
用于镰状细胞病治疗的血红蛋白调节剂
- 批准号:
9147091 - 财政年份:2014
- 资助金额:
$ 21.7万 - 项目类别:
Rational Design of Novel Estrogen Receptor Antagonists
新型雌激素受体拮抗剂的合理设计
- 批准号:
7174671 - 财政年份:2004
- 资助金额:
$ 21.7万 - 项目类别:
相似国自然基金
猪粪水热炭对红壤-蔬菜系统中抗生素抗性基因的风险控制及其机理
- 批准号:42307038
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
生物炭对厌氧膜生物反应器抑制畜禽养殖废水中抗生素抗性基因的调控作用和机制
- 批准号:52300210
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
蚯蚓-菌根协同消减抗生素抗性基因的微生物驱动机制
- 批准号:32301448
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于高通量测序和培养组学的伴侣动物-人抗生素抗性基因分布特征及传播研究
- 批准号:82373646
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
手性酰胺类农药污染的农业土壤中抗生素抗性基因传播扩散的对映选择性机制
- 批准号:42377238
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Bacterial and Molecular Determinants of Mycobacterial Impermeability
分枝杆菌不渗透性的细菌和分子决定因素
- 批准号:
10749613 - 财政年份:2023
- 资助金额:
$ 21.7万 - 项目类别:
Multiscale Modeling of B. Anthracis Surface Layer Assembly and Depolymerization by Nanobodies
纳米抗体对炭疽杆菌表面层组装和解聚的多尺度建模
- 批准号:
10432488 - 财政年份:2022
- 资助金额:
$ 21.7万 - 项目类别:
Project 3: Defining and defeating the mechanisms of outer membrane biogenesis in Gram-negative bacteria
项目 3:定义并破解革兰氏阴性菌外膜生物发生机制
- 批准号:
10699956 - 财政年份:2022
- 资助金额:
$ 21.7万 - 项目类别:
High-Resolution Mapping of Bacterial Transcriptional Responses in Human-Associated Microbiota
人类相关微生物群中细菌转录反应的高分辨率图谱
- 批准号:
10710183 - 财政年份:2022
- 资助金额:
$ 21.7万 - 项目类别:
Direct detection and identification of antimicrobial resistance genes in bloodstream infections
血流感染中抗菌药物耐药基因的直接检测和鉴定
- 批准号:
10680500 - 财政年份:2022
- 资助金额:
$ 21.7万 - 项目类别: